Indonesian Political, Business & Finance News

New Hope for Vision: Cell Rejuvenation Therapy for Eye Cells Enters Clinical Trials

| | Source: Media Indonesia Translated from Indonesian | Technology
New Hope for Vision: Cell Rejuvenation Therapy for Eye Cells Enters Clinical Trials
Image: Media Indonesia

Imagine if eye cells damaged by ageing could be ‘reprogrammed’ to work as they did before. That idea is now being tested in humans through ER-100, an experimental therapy developed to treat optic nerve damage and potentially help restore visual function.

ER-100 was developed by biotechnology company Life Biosciences using a partial epigenetic reprogramming approach. The technology seeks to readjust gene activity within cells so that aged or damaged cells can function better again.

According to WIRED, Life Biosciences administered the first dose of ER-100 to patients in a Phase 1 clinical trial in 2026. The trial involves patients with two conditions that can damage the optic nerve: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION.

This initial stage is primarily intended to assess the therapy’s safety and tolerability. Researchers will also monitor several indicators of visual function to look for possible benefits from ER-100.

According to reports from Life Biosciences, the United States Food and Drug Administration (FDA) granted clearance for the Investigational New Drug (IND) application for ER-100 in January 2026, allowing the therapy to proceed towards testing in humans.

ER-100 uses three transcription factors known as OCT4, SOX2 and KLF4, or OSK. These are used to influence the epigenetic patterns of cells without altering the DNA sequence.

Its primary target is retinal ganglion cells (RGCs), the nerve cells that carry visual information from the retina to the brain. Damage to these cells can cause vision loss that is difficult to reverse with conventional treatments.

Citing Life Biosciences’ reports, preclinical studies in animals showed changes in epigenetic patterns and improved visual function after ER-100 was administered. These results formed the basis for developing the therapy towards human clinical trials.

Despite bringing new hope, ER-100 cannot yet be called a proven therapy capable of restoring human vision. Results from animal research do not always translate into the same effects in humans.

Based on information cited from Life Biosciences, the Phase 1 trial will focus on safety, tolerability, immune response and a number of measures of visual function.

The results of this stage will determine whether the therapy can continue development into studies with a larger number of patients.

If proven safe and effective, ER-100 could potentially open up a new approach to treating eye diseases related to ageing and nerve damage. For now, the therapy remains at the clinical investigation stage.

More from 15 September 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/new-hope-for-vision-cell-rejuvenation-therapy-for-eye-cells-enters-clinical-trials-1789455021)
Originally published by Media Indonesia (https://mediaindonesia.com/kesehatan/933537/harapan-baru-untuk-penglihatan-terapi-peremajaan-sel-mata-kini-masuk-uji-klinis), translated from Indonesian
Print